BeOne Medicines annual gross margin
2021
2022
2023
2024
2025
BeOne Medicines's gross margin was 87.49% for fiscal 2025.
View full BeOne Medicines company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 87.49% | +3.08 pp |
| 2024 | 2024-12-31 | 84.41% | −0.14 pp |
| 2023 | 2023-12-31 | 84.55% | +4.78 pp |
| 2022 | 2022-12-31 | 79.77% | −6.21 pp |
| 2021 | 2021-12-31 | 85.98% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 89.76% | +2.28 pp |
| Q1 2026 | 2026-03-31 | 88.95% | +3.72 pp |
| Q4 2025 | 2025-12-31 | 90.49% | +4.73 pp |
| Q3 2025 | 2025-09-30 | 86.09% | +3.10 pp |
| Q2 2025 | 2025-06-30 | 87.49% | +2.35 pp |
| Q1 2025 | 2025-03-31 | 85.23% | +1.85 pp |
| Q4 2024 | 2024-12-31 | 85.76% | +2.45 pp |
| Q3 2024 | 2024-09-30 | 82.98% | −4.69 pp |
| Q2 2024 | 2024-06-30 | 85.13% | +1.26 pp |
| Q1 2024 | 2024-03-31 | 83.38% | +1.64 pp |
| Q4 2023 | 2023-12-31 | 83.32% | — |
| Q3 2023 | 2023-09-30 | 87.67% | — |
| Q2 2023 | 2023-06-30 | 83.87% | — |
| Q1 2023 | 2023-03-31 | 81.74% | — |
Across the available reported history, BeOne Medicines's gross margin increased from 84.41% to 87.49%, a change of +3.08 percentage points. The latest reported quarter, Q2 2026, shows 89.76%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines filings at SEC.gov ↗